2023-07-31 10:00 New number of shares and votes in IBT Regulatory
The number of shares and votes in Infant Bacterial Therapeutics AB (publ) has changed due to the recently completed rights issue (for further information...
2023-07-04 08:30 IBT announces outcome of its rights issue Regulatory
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA...
The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis. Infants suffering from gastroschisis suffer from risks...
“IBT announced earlier today that the Data Monitoring Committee (DMC) has performed the planned safety analysis of the study data of 1,403 babies...
In accordance with the study protocol, the independent Data Monitoring Committee (DMC) has performed the final planned safety analysis of Infant Bacterial...
Infant Bacterial Therapeutics AB (IBT) announces today that the European Patent Office has approved its patent application for Lactobacillus reuteri. The...
2023-06-13 11:15 IBT publishes prospectus Regulatory
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA...
At the Extraordinary General Meeting of Infant Bacterial Therapeutics AB (publ) on June 9, 2023, it was resolved to approve the Board of Directors&rsquo...
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Extraordinary General Meeting...
2023-05-16 23:00 IBT resolves on a rights issue Regulatory MAR
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA...

Subscribe to our press releases